Townsquare Capital LLC Has $1.07 Million Holdings in Zai Lab Limited Unsponsored ADR $ZLAB

Key Points

• Townsquare Capital LLC increased its stake in Zai Lab Limited by 219% in Q1, acquiring 20,346 additional shares, totaling 29,636 shares with a value of approximately $1,071,000.
• Equities analysts have mixed ratings for Zai Lab, with a consensus rating of "Moderate Buy" and a average price target of $57.22.
• Insider trading activity showed significant sales, with CEO Ying Du selling 50,000 shares for about $1.74 million, representing an 8.52% decrease in ownership.

Townsquare Capital LLC increased its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 219.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,636 shares of the company's stock after purchasing an additional 20,346 shares during the quarter. Townsquare Capital LLC's holdings in Zai Lab were worth $1,071,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oppenheimer Asset Management Inc. bought a new stake in shares of Zai Lab in the 1st quarter worth approximately $603,000. BNP Paribas Financial Markets raised its holdings in shares of Zai Lab by 1,439.8% in the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company's stock worth $517,000 after purchasing an additional 18,472 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Zai Lab by 8,090.8% in the 4th quarter. Wells Fargo & Company MN now owns 40,954 shares of the company's stock worth $1,073,000 after purchasing an additional 40,454 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Zai Lab during the fourth quarter valued at approximately $976,000. Finally, Northern Trust Corp raised its holdings in shares of Zai Lab by 117.8% during the fourth quarter. Northern Trust Corp now owns 49,365 shares of the company's stock valued at $1,293,000 after acquiring an additional 26,700 shares during the period. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Stock Down 0.3%

ZLAB stock traded down $0.12 during trading hours on Tuesday, hitting $35.57. The company's stock had a trading volume of 62,848 shares, compared to its average volume of 974,789. The company has a market capitalization of $3.95 billion, a PE ratio of -17.44 and a beta of 1.03. Zai Lab Limited Unsponsored ADR has a 12 month low of $16.83 and a 12 month high of $44.34. The stock has a 50 day moving average price of $36.63 and a two-hundred day moving average price of $33.64.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. Sell-side analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZLAB. Citigroup restated a "buy" rating and set a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a report on Monday, June 30th. Finally, Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Zai Lab presently has a consensus rating of "Moderate Buy" and an average target price of $57.22.

Insiders Place Their Bets

In related news, CFO Yajing Chen sold 1,438 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total transaction of $50,933.96. Following the completion of the sale, the chief financial officer directly owned 16,720 shares of the company's stock, valued at approximately $592,222.40. This represents a 7.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ying Du sold 46,387 shares of the company's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $35.47, for a total transaction of $1,645,346.89. Following the sale, the chief executive officer directly owned 536,962 shares of the company's stock, valued at approximately $19,046,042.14. This represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,687 shares of company stock valued at $7,637,554 over the last ninety days. Corporate insiders own 4.96% of the company's stock.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.